Nippon Rika
Japan Updated 9 July 2026
Nippon Rika is an API manufacturer based in Japan. It holds 2 active US drug master files and 2 valid CEPs across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 4 July 2025 as VAI.
2
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 4 July 2025 VAI US FDA
- 9 August 2018 NAI US FDA
- 13 February 2015 VAI US FDA
- 22 September 2011 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Japan, Japan | 3002807731 |
| Tokyo, Japan | Not on file |
What they file, and where
| Molecule | Regulators | Docs |
| Tyrosine | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Acetylcysteine | EDQM, US FDA | 2 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Nippon Rika comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 4 July 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates